1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)

Mckean, M., Chmielowski, B., Butler, M. O., Carvajal, R., Rodon, J., Carlino, M., Kim, K. B., Wise-draper, T., Khan, S., Salama, A. K. S., Moser, J., Reeves, J., Wilner, K. D., Maurer, M., Abed, M., Mitchell, B., Beaupre, D., & Orloff, M. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology, 34, S651. https://doi.org/10.1016/j.annonc.2023.09.2215
Authors:
Meredith McKean
Bartosz Chmielowski
Marcus O. Butler
R. Carvajal
Jordi Rodón
Matteo S. Carlino
K.B. Kim
Trisha M. Wise‐Draper
Shaheer Khan
Tara C. Gangadhar
Justin C. Moser
James A. Reeves
Keith D. Wilner
Mathew S. Maurer
Masoumeh Abed
Gregory Moore
Darrin M. Beaupre
Marlana Orloff
Affiliated Authors:
Shaheer Khan
Columbia Affiliation:
Subjects:
Ocular Cancer Research and Treatment (OpenAlex Topic)
Diagnosis and Treatment of Multiple Myeloma (OpenAlex Topic)
Genomic Landscape of Cancer and Mutational Signatures (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2023.09.2215
DOI:
10.1016/j.annonc.2023.09.2215
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: